Molecular partners provides update from ACTIVE-3 global clinical study of ensovibep in patients hospitalized with COVID-19

Molecular Partners, Press Release, Nov 2021
News release reporting that ensovibep was terminated for futility in ACTIV-3. 470 patients had been randomized.
Important missing comments or errors? Let us know.
Molecular Partners et al., 16 Nov 2021, Randomized Controlled Trial, multiple countries, preprint, 1 author.
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0